Trastuzumab (Herceptin®) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients
Marc Salzberg(University Hospital of Basel), Christoph Rochlitz, Daniel Rauch(Washington University in St. Louis), Jean-Alexandre Bauer(Centre Hospitalier Universitaire Vaudois), Markus Borner(University of Bern), Rudolf Morant
Cited by 22
Related Papers
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
|The Lancet Respiratory Medicine|2017|184
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
|Annals of Oncology|2001|151